HRP20180425T1 - Čvrste kompozicije koje sadrže agonist glp-1 i sol n-(8-(2-hidroksibenzoil)amino)kaprilne kiseline - Google Patents

Čvrste kompozicije koje sadrže agonist glp-1 i sol n-(8-(2-hidroksibenzoil)amino)kaprilne kiseline Download PDF

Info

Publication number
HRP20180425T1
HRP20180425T1 HRP20180425TT HRP20180425T HRP20180425T1 HR P20180425 T1 HRP20180425 T1 HR P20180425T1 HR P20180425T T HRP20180425T T HR P20180425TT HR P20180425 T HRP20180425 T HR P20180425T HR P20180425 T1 HRP20180425 T1 HR P20180425T1
Authority
HR
Croatia
Prior art keywords
mmol
amino
composition according
hydroxybenzoyl
salt
Prior art date
Application number
HRP20180425TT
Other languages
English (en)
Croatian (hr)
Inventor
Per Sauerberg
Simon Bjerregaard
Flemming Seier Nielsen
Original Assignee
Novo Nordisk A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43903993&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20180425(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novo Nordisk A/S filed Critical Novo Nordisk A/S
Publication of HRP20180425T1 publication Critical patent/HRP20180425T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Reproductive Health (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
HRP20180425TT 2010-12-16 2011-12-16 Čvrste kompozicije koje sadrže agonist glp-1 i sol n-(8-(2-hidroksibenzoil)amino)kaprilne kiseline HRP20180425T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP10195285 2010-12-16
US201061425087P 2010-12-20 2010-12-20
EP11805824.7A EP2651398B1 (en) 2010-12-16 2011-12-16 Solid compositions comprising a glp-1 agonist and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid
PCT/EP2011/073060 WO2012080471A1 (en) 2010-12-16 2011-12-16 Solid compositions comprising a glp-1 agonist and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid

Publications (1)

Publication Number Publication Date
HRP20180425T1 true HRP20180425T1 (hr) 2018-04-20

Family

ID=43903993

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20180425TT HRP20180425T1 (hr) 2010-12-16 2011-12-16 Čvrste kompozicije koje sadrže agonist glp-1 i sol n-(8-(2-hidroksibenzoil)amino)kaprilne kiseline

Country Status (21)

Country Link
US (7) US9278123B2 (enExample)
EP (3) EP2651398B1 (enExample)
JP (2) JP5902194B2 (enExample)
KR (1) KR101925620B1 (enExample)
CN (2) CN105963685B (enExample)
AU (1) AU2011343190B2 (enExample)
BR (1) BR112013014942B1 (enExample)
CA (1) CA2821886A1 (enExample)
DK (2) DK3326620T3 (enExample)
ES (1) ES2661676T3 (enExample)
HR (1) HRP20180425T1 (enExample)
HU (1) HUE036066T2 (enExample)
LT (1) LT2651398T (enExample)
MX (2) MX345501B (enExample)
PL (2) PL3326620T3 (enExample)
PT (1) PT2651398T (enExample)
RS (2) RS56998B1 (enExample)
RU (1) RU2600440C3 (enExample)
SI (2) SI3326620T1 (enExample)
SM (1) SMT201800117T1 (enExample)
WO (1) WO2012080471A1 (enExample)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX345501B (es) 2010-12-16 2017-02-02 Novo Nordisk As Composiciones solidas que comprenden agonista de glp-1 y sal del acido n-(8-(2-hidroxibenzoil)amino)caprilico.
KR101972836B1 (ko) 2011-04-12 2019-04-29 노보 노르디스크 에이/에스 이중 아실화된 ｇｌｐ-1 유도체
WO2013139695A1 (en) 2012-03-22 2013-09-26 Novo Nordisk A/S Compositions comprising a delivery agent and preparation thereof
EP2827885B1 (en) * 2012-03-22 2018-08-15 Novo Nordisk A/S Compositions of glp-1 peptides and preparation thereof
HRP20190489T1 (hr) 2012-03-22 2019-05-03 Novo Nordisk A/S Pripravci koji sadrže sredstvo za unošenje i njihova priprava
US9993430B2 (en) * 2012-06-20 2018-06-12 Novo Nordisk A/S Tablet formulation comprising semaglutide and a delivery agent
HRP20251088T1 (hr) 2012-07-01 2025-11-07 Novo Nordisk A/S Upotreba dugodjelujućih peptida glp‑1
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
SG10201705097PA (en) 2012-12-21 2017-07-28 Sanofi Sa Functionalized exendin-4 derivatives
US9457086B2 (en) 2013-03-05 2016-10-04 Enteris Biopharma, Inc. Pharmaceuticals for oral delivery
CN104055735B (zh) * 2013-03-22 2016-08-03 深圳翰宇药业股份有限公司 一种萨摩鲁泰的脂质体及其制备方法
SMT201800492T1 (it) 2013-05-02 2018-11-09 Novo Nordisk As Dosaggio orale di composti di glp-1
WO2015086729A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/gip receptor agonists
EP3080149A1 (en) 2013-12-13 2016-10-19 Sanofi Dual glp-1/glucagon receptor agonists
WO2015086730A1 (en) 2013-12-13 2015-06-18 Sanofi Non-acylated exendin-4 peptide analogues
TW201609795A (zh) 2013-12-13 2016-03-16 賽諾菲公司 作為雙重ｇｌｐ－１／ｇｉｐ受體促效劑的艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
EP3006045B3 (en) * 2014-10-07 2021-03-17 Cyprumed GmbH Pharmaceutical formulations for the oral delivery of peptide or protein drugs
CN105777872B (zh) * 2014-12-16 2019-06-07 深圳翰宇药业股份有限公司 一种萨摩鲁肽的纯化方法
US9833411B2 (en) 2015-01-12 2017-12-05 Enteris Biopharma, Inc. Solid oral dosage forms
JP7211704B2 (ja) * 2015-01-29 2023-01-24 ノヴォ ノルディスク アー／エス Ｇｌｐ－１アゴニスト及び腸溶コーティングを含む錠剤
JP6925969B2 (ja) * 2015-02-09 2021-08-25 エンテラ バイオ エルティーディー． 医薬組成物
WO2016168388A2 (en) 2015-04-14 2016-10-20 Palatin Technologies, Inc. Therapies for obesity, diabetes and related indications
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
AR105284A1 (es) 2015-07-10 2017-09-20 Sanofi Sa Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
ES2835033T3 (es) 2016-03-03 2021-06-21 Novo Nordisk As Derivados de GLP-1 y sus usos
KR20180135012A (ko) * 2016-04-28 2018-12-19 노보 노르디스크 에이/에스 심혈관 병태에서의 세마글루타이드
IL321113A (en) 2016-08-17 2025-07-01 Entera Bio Ltd Formulations for oral administration of active agents
JOP20190060A1 (ar) 2016-09-26 2019-03-26 Chugai Pharmaceutical Co Ltd مشتق بيرازولو بيريدين له تأثير مساعد لمستقبل glp-1
CA3061479A1 (en) * 2017-04-25 2018-11-01 Proteus Digital Health, Inc. Lisinopril compositions with an ingestible event marker
TWI797133B (zh) * 2017-06-09 2023-04-01 丹麥商諾佛 儂迪克股份有限公司 用於經口投予的固體組成物
CN110809464A (zh) 2017-06-27 2020-02-18 株式会社培旺精廉宅 粘膜附着性口服制剂
TWI847306B (zh) 2017-08-24 2024-07-01 丹麥商諾佛 儂迪克股份有限公司 Ｇｌｐ-１組成物及其用途
IL322969A (en) 2017-10-12 2025-10-01 Novo Nordisk As Semaglutide in medical therapy
EP4299118A3 (en) * 2018-02-02 2024-04-10 Novo Nordisk A/S Solid compositions comprising a glp-1 agonist, a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant
TWI829687B (zh) * 2018-05-07 2024-01-21 丹麥商諾佛 儂迪克股份有限公司 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物
JP7422754B2 (ja) 2018-10-26 2024-01-26 ノヴォ ノルディスク アー／エス 安定性セマグルチド組成物およびその使用
JP7560467B2 (ja) 2019-01-24 2024-10-02 ノヴォ ノルディスク アー／エス ローラコンパクタおよびローラコンパクタを使用する乾式造粒の方法
EP3930757A1 (en) 2019-03-01 2022-01-05 President And Fellows Of Harvard College Methods and compositions for protein delivery
US12458612B2 (en) 2019-04-10 2025-11-04 Genfit Combination therapy comprising compounds of formula (I) and GLP-1 receptor agonists
CA3144618A1 (en) 2019-08-07 2021-02-11 Novo Nordisk A/S Solid compositions comprising an egf(a) derivative and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid
JP2022543826A (ja) * 2019-08-07 2022-10-14 ノヴォ ノルディスク アー／エス Ｐｙｙ化合物とｎ－（８－（２－ヒドロキシベンゾイル）アミノ）カプリル酸の塩とを含む固形組成物
EP4025192B1 (en) 2019-09-02 2025-12-03 Novo Nordisk A/S Process for producing a tablet comprising glp-1 peptides
EP4025353B1 (en) 2019-09-06 2024-11-06 Novo Nordisk A/S Method and equipment for fractionation of granules for use in pharmaceutical compositions
CN114728042A (zh) * 2019-11-06 2022-07-08 诺和诺德股份有限公司 用于痴呆的glp-1受体激动剂
US20230000949A1 (en) 2019-11-07 2023-01-05 Novo Nordisk A/S Solid compositions comprising a pcsk9 inhibitor and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid
CN114641276A (zh) 2019-11-07 2022-06-17 诺和诺德股份有限公司 包含glp-1激动剂、sglt2抑制剂和n-(8-(2-羟基苯甲酰基)氨基)辛酸的盐的固体组合物
US20230165939A1 (en) * 2020-04-29 2023-06-01 Novo Nordisk A/S Solid compositions comprising a glp-1 agonist and histidine
CN113735734B (zh) * 2020-05-29 2023-12-08 杭州先为达生物科技股份有限公司 N-[8-(2-羟基苯甲酰基)氨基]辛酸钾晶体多晶型物及其制备方法和用途
KR102901689B1 (ko) 2020-05-29 2025-12-22 항저우 사이윈드 바이오사이언시즈 컴퍼니 리미티드 칼륨 n-[8-(2-히드록시벤조일)아미노]옥타노에이트결정 다형체 및 이의 제조 방법과 용도
CA3184717A1 (en) 2020-07-22 2022-01-27 Patrick J. KNERR Co-agonists at glp-1 and gip receptors suitable for oral delivery
CN112274633B (zh) * 2020-09-16 2023-11-07 广州新济薇娜生物科技有限公司 索马鲁肽降糖减重微针贴片及其制备方法和应用
CN112062690A (zh) * 2020-11-11 2020-12-11 北京先为达生物科技有限公司 N-[8-(2-羟基苯甲酰基)氨基]辛酸钾晶体多晶型物及其制备方法和用途
CR20230308A (es) 2020-12-11 2023-09-08 Civi Biopharma Inc Entrega oral de conjugados antisentido que tienen por blanco a pcsk9
TW202440619A (zh) 2020-12-18 2024-10-16 丹麥商諾佛 儂迪克股份有限公司 Glp-1及澱粉素受體之共促效劑
FR3120189B1 (fr) 2021-03-01 2024-11-29 Farid Bennis Composition pharmaceutique pour une administration par voie orale d’un agoniste du récepteur du GLP-1
JP7772778B2 (ja) 2021-03-24 2025-11-18 塩野義製薬株式会社 縮合環を有するｇｌｐ－１受容体作動薬を含有する医薬組成物
US11667614B2 (en) 2021-04-16 2023-06-06 Navinta III Inc. Process for the preparation of highly pure Salcaprozic Acid and pharmaceutically acceptable salts thereof
EP4323330B1 (en) 2021-04-16 2025-12-10 Navinta III Inc Process for the preparation of highly pure salcaprozic acid and pharmaceutically acceptable salts thereof
CR20230471A (es) 2021-04-22 2023-11-01 Civi Biopharma Inc Administración oral de oligonucleótidos
EP4360645A4 (en) * 2021-06-25 2025-09-10 Gan & Lee Pharmaceuticals Co Ltd PHARMACEUTICAL COMPOSITION CONTAINING A GLP-1 COMPOUND
MX2024000768A (es) 2021-07-15 2024-02-12 Novo Nordisk As Comprimido que comprende una sal del acido n-(8-(2-hidroxibenzoil) amino)caprilico.
PE20241303A1 (es) 2021-07-16 2024-06-24 Novo Nordisk As Forma polimorfica a de n-(8-(2-hidroxibenzoil)amino)caprilato de sodio
US20230053812A1 (en) * 2021-07-27 2023-02-23 Aurobindo Pharma Ltd Stable peptide formulations for oral use
WO2023012263A1 (en) 2021-08-04 2023-02-09 Novo Nordisk A/S Solid oral peptide formulations
WO2023065231A1 (en) * 2021-10-21 2023-04-27 Guangzhou Dazhou Biomedicine Ltd. Oral delivery of therapeutic agents
WO2023086499A1 (en) 2021-11-10 2023-05-19 I2O Therapeutics, Inc. Ionic liquid compositions
EP4180060A1 (en) * 2021-11-15 2023-05-17 Adocia Solid compositions comprising a peptide or a protein and an acylated amino acid
EP4299057A1 (en) * 2022-06-30 2024-01-03 Adocia Solid compositions comprising a peptide or a protein and an acylated amino acid
TW202330584A (zh) 2022-01-20 2023-08-01 丹麥商諾佛 儂迪克股份有限公司 前藥及其用途
MX2024010388A (es) * 2022-02-24 2024-09-04 Entera Bio Ltd Formulaciones que comprenden un polimero neutralizante de acido para la administracion oral del peptido-1 similar al glucagon y sus analogos.
WO2023179796A1 (en) * 2022-03-25 2023-09-28 Beijing Ql Biopharmaceutical Co., Ltd. Pharmaceutical compositions of polypeptide conjugates and methods of uses thereof
WO2024017139A1 (zh) * 2022-07-20 2024-01-25 成都海博为药业有限公司 一种含有glp-1受体激动剂类似物的药物组合物
CN119907794A (zh) 2022-09-22 2025-04-29 盐野义制药株式会社 具有glp-1受体激动剂作用的稠环化合物
WO2024110614A1 (en) 2022-11-25 2024-05-30 Novo Nordisk A/S Oral administration of peptide therapeutics, such as glp-1
AU2023415591A1 (en) 2022-12-30 2025-08-14 Algipharma As Compositions and methods to increase the systemic bioavailability of a polypeptide therapeutic agent undergoing oral administration
WO2025017454A1 (en) * 2023-07-14 2025-01-23 Biophore India Pharmaceuticals Pvt. Ltd Stable solid dispersions of salcaprozate with various active pharmaceutical ingredients
TW202540155A (zh) 2023-11-30 2025-10-16 丹麥商諾佛 儂迪克股份有限公司 Glp-1、gip及澱粉素受體之三重促效劑
WO2025169190A2 (en) 2024-02-06 2025-08-14 Opko Biologics Ltd. Modified oxyntomodulin and methods of use thereof
WO2025220032A1 (en) * 2024-04-16 2025-10-23 Bhami's Research Laboratory, Pvt. Ltd. Polypeptide formulations for oral delivery
CN118319871B (zh) * 2024-04-19 2025-08-05 鲁南新时代生物技术有限公司 一种司美格鲁肽药物组合物
AU2024204465A1 (en) * 2024-06-28 2026-01-15 Merdury Biopharmaceutical Corporation Oral peptide drug structure and manufacturing method thereof
WO2026017601A1 (en) 2024-07-15 2026-01-22 F. Hoffmann-La Roche Ag Novel formulations for oral administration of oligonucleotides

Family Cites Families (192)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR8701121A (pt) 1986-03-12 1988-01-05 Glaxo Group Ltd Processo para a preparacao de um composto e processo para combate a pestes
US5545618A (en) 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
DE69129226T2 (de) 1990-01-24 1998-07-30 Douglas I. Woodside Calif. Buckley Glp-1-analoga verwendbar in der diabetesbehandlung
DK39892D0 (da) 1992-03-25 1992-03-25 Bernard Thorens Peptid
EP0692971A4 (en) 1993-03-29 1997-11-12 Univ Cincinnati PEPTID YY ANALOGS AND USES THEREFOR
US5705483A (en) 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
EP0803255A4 (en) 1994-06-03 1999-06-30 Tsumura & Co MEDICINAL COMPOSITION
US5512549A (en) 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
US5574010A (en) 1994-11-14 1996-11-12 The Regents Of The University Of California Treatment of pancreatic tumors with peptide YY and analogs thereof
US5869602A (en) 1995-03-17 1999-02-09 Novo Nordisk A/S Peptide derivatives
US5866536A (en) 1995-03-31 1999-02-02 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
BR9604880A (pt) 1995-03-31 1998-05-19 Emisphere Tech Inc Composto composição forma de unidade de dosagem métodos para administração de um agente biologicamente ativo para preparar uma composição para administração de um agente ativo e para preparar um composto e composição farmacológica
US5650386A (en) 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
SE9600070D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
US7235627B2 (en) 1996-08-30 2007-06-26 Novo Nordisk A/S Derivatives of GLP-1 analogs
IL128332A0 (en) 1996-08-30 2000-01-31 Novo Nordisk As GLP-1 derivatives
US6458924B2 (en) 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
DE69732572T2 (de) 1996-11-12 2005-12-29 Novo Nordisk A/S Verwendung von glp-1 peptiden
AU1159897A (en) 1996-11-13 1998-06-03 University Of Cincinnati, The Analogs of peptide yy and uses thereof
US5773647A (en) 1997-02-07 1998-06-30 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
EP0908515A3 (en) 1997-09-16 2000-04-26 Smithkline Beecham Plc Pancreatic polypeptide
AU2610599A (en) 1998-02-27 1999-09-15 Novo Nordisk A/S N-terminally truncated glp-1 derivatives
JP2002506792A (ja) 1998-02-27 2002-03-05 ノボ ノルディスク アクティーゼルスカブ Ｎ末端修飾ｇｌｐ−１誘導体
WO1999043706A1 (en) 1998-02-27 1999-09-02 Novo Nordisk A/S Derivatives of glp-1 analogs
AU3247799A (en) 1998-02-27 1999-09-15 Novo Nordisk A/S Glp-1 derivatives of glp-1 and exendin with protracted profile of action
EP1061946B1 (en) 1998-02-27 2004-04-28 Novo Nordisk A/S Glp-1 derivatives with helix-content exceeding 25 %, forming partially structured micellar-like aggregates
US6046167A (en) 1998-03-25 2000-04-04 University Of Cincinnati Peptide YY analogs
IL139913A0 (en) 1998-06-08 2002-02-10 Schering Corp Neuropeptide y5 receptor antagonists
SE9802080D0 (sv) 1998-06-11 1998-06-11 Hellstroem Pharmaceutical composition for the treatment of functional dyspepsia and/or irritable bowel syndrome and new use of substances therein
EP1100530B1 (en) 1998-07-31 2003-10-08 Novo Nordisk A/S In-vitro stimulation of beta cell proliferation
MY155270A (en) 1998-09-24 2015-09-30 Lilly Co Eli Use of glp-1 or analogs in treatment of stroke
CN1495198A (zh) 1998-12-07 2004-05-12 �о���Ӧ�ÿ�ѧЭ��ɷ����޹�˾ 胰高血糖素样肽-1的类似物
AU3357800A (en) 1999-02-05 2000-08-25 Emisphere Technologies, Inc. Method of preparing alkylated salicylamides
WO2000050012A1 (en) 1999-02-22 2000-08-31 Elan Corporation, Plc Solid oral dosage form containing an enhancer
WO2000048589A1 (en) 1999-02-22 2000-08-24 Emisphere Holdings, Inc. Solid oral dosage form containing heparin or a heparinoid in combination with a carrier
US7658938B2 (en) 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
CN1372570A (zh) 1999-04-30 2002-10-02 安米林药品公司 修饰的exendin和exendin激动剂
EP1180121B9 (en) 1999-05-17 2004-09-08 Conjuchem, Inc. Long lasting insulinotropic peptides
US7601691B2 (en) 1999-05-17 2009-10-13 Conjuchem Biotechnologies Inc. Anti-obesity agents
EP1076066A1 (en) 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
GB9923436D0 (en) 1999-10-04 1999-12-08 American Home Prod Pharmaceutical compositions
US6793934B1 (en) 1999-12-08 2004-09-21 Shire Laboratories, Inc. Solid oral dosage form
AU2001275231A1 (en) 2000-06-02 2001-12-11 Emisphere Technologies, Inc. Method of preparing salicylamides
US7049283B2 (en) 2000-12-06 2006-05-23 Novartis Ag Pharmaceutical compositions for the oral delivery of pharmacologically active agents
UA93662C2 (uk) 2000-12-07 2011-03-10 Эли Лилли Энд Компани Гетерологічний пептидильований глюкагон-подібний білок та його застосування для виготовлення лікарського засобу для лікування пацієнтів, що страждають на ожиріння або інсулінонезалежний цукровий діабет
AU2002228608A1 (en) 2000-12-13 2002-06-24 Eli Lilly And Company Amidated glucagon-like peptide-1
CA2431800C (en) 2000-12-14 2014-07-08 Amylin Pharmaceuticals, Inc. Peptide yy and peptide yy agonists for treatment of metabolic disorders
US6589938B2 (en) 2001-06-29 2003-07-08 National University Of Singapore Use of angiotensin I derivatives as an agent for the treatment and prevention of infarction-related cardiac injuries and disorders
US20030068356A1 (en) 2001-07-10 2003-04-10 Pather S. Indiran Sequential drug delivery systems
CA2455963C (en) 2001-07-31 2017-07-04 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Glp-1, exendin-4, peptide analogs and uses thereof
BR0212985A (pt) 2001-09-24 2005-08-30 Imp College Innovations Ltd Uso de pyy ou de um agonista do mesmo na preparação de medicamentos para tratamento de distúrbios associados com excesso de peso
AU2002352974A1 (en) 2001-11-29 2003-06-10 Emisphere Technologies, Inc. Formulations for oral administration of cromolyn sodium
US8058233B2 (en) 2002-01-10 2011-11-15 Oregon Health And Science University Modification of feeding behavior using PYY and GLP-1
JP2005526020A (ja) 2002-02-01 2005-09-02 ファイザー・プロダクツ・インク アジスロマイシンの乾式造粒配合物
CN1332711C (zh) 2002-02-20 2007-08-22 埃米球科技有限公司 施用glp－1分子的方法
MXPA04012497A (es) 2002-07-04 2005-07-14 Zealand Pharma As Glp-1 y metodos para tratar la diabetes.
JP2004131398A (ja) 2002-10-08 2004-04-30 Taihei Chemical Industrial Co Ltd 錠剤用滑沢剤
EP1583549A4 (en) 2003-01-17 2006-10-04 Sod Conseils Rech Applic YY PEPTIDE ANALOGS
WO2004067548A2 (en) 2003-01-31 2004-08-12 Theratechnologies Inc. Chemically modified metabolites of regulatory peptides and methods of producing and using same
EA009366B1 (ru) 2003-03-19 2007-12-28 Эли Лилли Энд Компани Связанные с полиэтиленгликолем соединения гпп-1
AU2004241242A1 (en) 2003-05-14 2004-12-02 Emisphere Technologies, Inc. Compositions for delivering peptide YY and PYY agonists
US7572581B2 (en) 2003-06-30 2009-08-11 Roche Molecular Systems, Inc. 2′-terminator nucleotide-related methods and systems
PT1651248E (pt) 2003-07-11 2009-11-10 Novartis Ag Composições farmacêuticas para dose oral compreendendo um agente de administração na forma micronizada
JP2007501811A (ja) 2003-08-08 2007-02-01 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 治療的な関心対象のタンパク質に対する遅延分子の選択的な化学物質接合のためのガラクトースオキシダーゼの使用。
CN101380476A (zh) 2003-09-19 2009-03-11 诺沃挪第克公司 治疗肽的清蛋白结合型衍生物
CA2539253A1 (en) 2003-09-19 2005-03-31 Novo Nordisk A/S Albumin-binding derivatives of therapeutic peptides
JP2007537981A (ja) 2003-09-19 2007-12-27 ノボ　ノルディスク　アクティーゼルスカブ 新規の血漿タンパク質親和性タグ
DK3300721T4 (da) 2003-11-20 2025-03-03 Novo Nordisk As Propylenglycol-holdige peptidformuleringer hvilke er optimale til fremstilling og til anvendelse i injektionsindretninger
AU2004298424A1 (en) 2003-12-18 2005-06-30 Novo Nordisk A/S Novel GLP-1 compounds
BRPI0417684A (pt) 2003-12-18 2007-03-20 Novo Nordisk As composto, composição farmacêutica, e, uso de um composto
US20060286129A1 (en) 2003-12-19 2006-12-21 Emisphere Technologies, Inc. Oral GLP-1 formulations
US8603969B2 (en) 2004-02-11 2013-12-10 Amylin Pharmaceuticals, Llc Pancreatic polypeptide family motifs and polypeptides comprising the same
BRPI0507594A (pt) 2004-02-11 2007-07-03 Amylin Pharmaceuticals Inc polipetìdeos hìbridos com propriedades selecionáveis
ATE519495T1 (de) 2004-03-17 2011-08-15 7Tm Pharma As Y4-selektiver rezeptoragonist pp2-36 für therapeutische eingriffe
CA2559838A1 (en) 2004-03-17 2005-09-29 7Tm Pharma A/S Y2 selective receptor agonists for therapeutic interventions
CA2560166A1 (en) 2004-03-17 2005-09-29 7Tm Pharma A/S Y2/y4 selective receptor agonists for therapeutic interventions
CN101361967A (zh) 2004-03-17 2009-02-11 7Tm制药联合股份有限公司 用于治疗性干预的y2/y4选择性受体激动剂
WO2005099672A1 (en) 2004-04-13 2005-10-27 Ranbaxy Laboratories Limited A modified release pharmaceutical formulation comprising amoxicillin and clavulanate
AU2005240206B2 (en) 2004-05-06 2011-04-07 Emisphere Technologies, Inc. Solid dosage form of wetted heparin
SG153039A1 (en) 2004-05-06 2009-06-29 Emisphere Tech Inc Crystalline polymorphic forms of monosodium n-[8- (2hydroxybenzoyl)amino]caprylate
NZ551196A (en) * 2004-05-14 2010-08-27 Emisphere Tech Inc Compounds and compositions for delivering active agents
GB0412181D0 (en) 2004-06-01 2004-06-30 Celltech R&D Ltd Biological products
WO2005121090A1 (en) 2004-06-02 2005-12-22 Abbott Laboratories Substituted piperidines that have antiangiogenic activity
TW200611704A (en) 2004-07-02 2006-04-16 Bristol Myers Squibb Co Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions
US20070021346A1 (en) 2005-05-26 2007-01-25 Ewing William R N-terminally modified GLP-1 receptor modulators
CN101010339B (zh) 2004-07-02 2011-11-09 布里斯托尔-迈尔斯斯奎布公司 人类胰高血糖素样肽-1调节剂及它们在治疗糖尿病及相关病况中的用途
ES2542228T3 (es) 2004-07-08 2015-08-03 Novo Nordisk A/S Marcas de prolongación polipeptídica que comprenden un resto de tetrazol
JP5749879B2 (ja) 2004-07-12 2015-07-15 エミスフェアー・テクノロジーズ・インク ペプチドｙｙおよびペプチドｙｙアゴニストの送達用組成物
US7994119B2 (en) 2004-07-19 2011-08-09 University Of Cincinnati Compounds for control of appetite
JP2008509933A (ja) 2004-08-13 2008-04-03 エミスフェアー・テクノロジーズ・インク 送達剤のマイクロ粒子またはナノ粒子を含む医薬製剤
WO2006049681A2 (en) 2004-08-30 2006-05-11 Bayer Pharmaceuticals Corporation Selective neuropeptide y2 receptor agonists
JP5107713B2 (ja) 2004-10-07 2012-12-26 ノヴォ ノルディスク アー／エス 遅延性のエキセンディン−４化合物
WO2006037810A2 (en) 2004-10-07 2006-04-13 Novo Nordisk A/S Protracted glp-1 compounds
RU2007126522A (ru) 2004-12-09 2009-01-20 Радиал Корпорэйшин Лимитед (Au) Транспортировка материала для радиального пиления древесины
US7410949B2 (en) 2005-01-18 2008-08-12 Hoffmann-La Roche Inc. Neuropeptide-2 receptor (Y-2R) agonists and uses thereof
US20080153779A1 (en) 2005-02-01 2008-06-26 Jun Liao Gastric Retention and Controlled Release Delivery System
EP2256130B1 (en) 2005-02-02 2013-09-25 Novo Nordisk A/S Novel insulin derivatives
JP2008531059A (ja) 2005-03-04 2008-08-14 バイオレクシス ファーマシューティカル コーポレーション 改変トランスフェリン融合タンパク質
GB0504857D0 (en) 2005-03-09 2005-04-13 Imp College Innovations Ltd Novel compounds and their effects on feeding behaviour
BRPI0608516A2 (pt) 2005-03-18 2010-11-16 Novo Nordisk As análogo de glp-1, método para aumentar o tempo de ação em um paciente de um análogo de glp-1, composição farmacêutica, e, uso de um composto
TWI372629B (en) * 2005-03-18 2012-09-21 Novo Nordisk As Acylated glp-1 compounds
WO2006097535A2 (en) 2005-03-18 2006-09-21 Novo Nordisk A/S Peptide agonists of the glucagon family with secretin like activity
EP1863537A2 (en) 2005-03-18 2007-12-12 Novo Nordisk A/S Dimeric peptide agonists of the glp-1 receptor
EP1863449A2 (en) 2005-03-28 2007-12-12 Dexcel Pharma Technologies Ltd. Controlled absorption of statins in the intestine
US20090054326A1 (en) 2005-07-11 2009-02-26 Nastech Pharmaceutical Company Inc. Formulations for enhanced mucosal delivery of pyy
US8975227B2 (en) 2005-07-15 2015-03-10 Emisphere Technologies, Inc. Intraoral dosage forms of glucagon
CN101222942A (zh) 2005-07-18 2008-07-16 诺沃-诺迪斯克有限公司 用于治疗肥胖的肽
DK1971362T3 (en) 2005-08-19 2015-01-26 Amylin Pharmaceuticals Llc Exendin for treating diabetes and reducing body weight
US20070049557A1 (en) 2005-08-24 2007-03-01 Hashim Ahmed Solid pharmaceutical dosage forms comprising bisphosphonates and modified amino acid carriers
EP1934254A1 (en) 2005-09-21 2008-06-25 7TM Pharma A/S Y4 selective receptor agonists for therapeutic interventions
BRPI0520566A2 (pt) 2005-09-21 2009-05-19 7Tm Pharma As agonistas de receptores y2 seletivos para intervenções terapêuticas
WO2007061434A2 (en) 2005-11-10 2007-05-31 Nastech Pharmaceutical Company Inc. A pharmaceutical formulation of glp-1 and its use for treating a metabolic syndrome
US20080255048A1 (en) 2005-11-17 2008-10-16 Moise Azria Pharmaceutical Composition
WO2007065808A2 (en) 2005-12-07 2007-06-14 F. Hoffmann-La Roche Ag Neuropeptide-2 receptor-agonists
JP2009520693A (ja) 2005-12-08 2009-05-28 エムディーアールエヌエー，インコーポレイテッド 安定化されたエキセンディン製剤の粘膜送達
JP2009519296A (ja) 2005-12-14 2009-05-14 ノボ・ノルデイスク・エー／エス ポリペプチド延長タグ
US20070197445A1 (en) 2006-01-18 2007-08-23 University Of Cincinnati Compounds for control of appetite
CN101432025B (zh) 2006-03-21 2012-04-04 安米林药品公司 肽-肽酶抑制剂结合物及其使用方法
ES2426445T3 (es) 2006-04-07 2013-10-23 Merrion Research Iii Limited Forma de dosificación oral sólida que contiene un potenciador
US8927015B2 (en) 2006-04-12 2015-01-06 Emisphere Technologies, Inc. Formulations for delivering insulin
EP2015770B1 (en) 2006-05-09 2012-09-26 Novo Nordisk A/S Insulin derivative
CA2654566A1 (en) 2006-06-09 2007-12-21 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
US9364502B2 (en) 2006-06-28 2016-06-14 Emisphere Technologies, Inc. Gallium nitrate formulations
GB0613196D0 (en) 2006-07-03 2006-08-09 Imp Innovations Ltd Novel compounds and their effects on feeding behaviour
ES2296529B1 (es) 2006-08-07 2009-04-01 Laboratorios Farmaceuticos Rovi, S.A. Composicion farmaceutica con promotores de absorcion.
US20090318353A1 (en) 2006-08-25 2009-12-24 Novo Nordisk A/S Acylated Exendin-4 Compounds
KR101081149B1 (ko) 2006-09-07 2011-11-07 에미스페어 테크놀로지스, 인코포레이티드 Ｓｎａｃ(살카프로제이트 나트륨)의 제조 방법
PE20121528A1 (es) 2006-09-13 2012-12-12 Smithkline Beecham Corp Metodos para administrar agentes hipoglucemiantes de larga duracion
AR062925A1 (es) 2006-09-22 2008-12-17 Novartis Ag Metodo para fabricar tabletas que contienen agentes farmacologicamente activos
GB0621973D0 (en) 2006-11-03 2006-12-13 Philogen Spa Binding molecules and uses thereof
US20100069410A1 (en) 2006-12-01 2010-03-18 Emisphere Technologies Inc. acyclovir formulations
US20090099074A1 (en) 2007-01-10 2009-04-16 Conjuchem Biotechnologies Inc. Modulating food intake
JP2010516652A (ja) 2007-01-18 2010-05-20 ノボ・ノルデイスク・エー／エス 肥満の治療に使用される新規ペプチド
US20100022446A1 (en) 2007-01-18 2010-01-28 Novo Nordisk A/S Use of Peptides in Combination with Surgical Intervention for the Treatment of Obesity
ES2365648T3 (es) 2007-03-02 2011-10-07 Novartis Ag Administración oral de una calcitonina.
GB0708226D0 (en) 2007-04-27 2007-06-06 7Tm Pharma As Y-receptor agonists
EP2164466A1 (en) 2007-06-01 2010-03-24 Novo Nordisk A/S Spontaneously dispersible preconcentrates including a peptide drug in a solid or semisolid carrier
EP2171080A4 (en) 2007-06-12 2010-10-27 Glaxosmithkline Llc PROCESS FOR DETECTING PROTEIN IN PLASMA
JP2010533157A (ja) 2007-07-09 2010-10-21 インペリアル イノベーションズ リミテッド ヒト膵臓ポリペプチド（ｈｐｐ）類似体および摂食行動に対するそれらの影響
CA2697504A1 (en) 2007-08-29 2009-03-12 The Regents Of The University Of California Salicylanilide modified peptides for use as oral therapeutics
ES2672770T3 (es) 2007-09-05 2018-06-18 Novo Nordisk A/S Derivados del péptido-1 similar al glucagón y su uso farmacéutico
US20100292133A1 (en) 2007-09-05 2010-11-18 Novo Nordisk A/S Truncated glp-1 derivaties and their therapeutical use
US20100261637A1 (en) 2007-09-05 2010-10-14 Novo Nordisk A/S Peptides derivatized with a-b-c-d- and their therapeutical use
JP2010538981A (ja) 2007-09-11 2010-12-16 モンドバイオテック ラボラトリーズ アクチエンゲゼルシャフト 単独でまたはペプチドＧｌｙ−Ａｒｇ−Ｇｌｙ−Ａｓｐ−Ａｓｎ−Ｐｒｏ−ＯＨと組み合わせて用いる、治療剤としてのペプチドＨｉｓ−Ｓｅｒ−Ｌｅｕ−Ｇｌｙ−Ｌｙｓ−Ｔｒｐ−Ｌｅｕ−Ｇｌｙ−Ｈｉｓ−Ｐｒｏ−Ａｓｐ−Ｌｙｓ−Ｐｈｅの使用
WO2009042922A2 (en) 2007-09-27 2009-04-02 Amylin Pharmaceuticals, Inc. Peptide-peptidase inhibitor conjugates and methods of making and using same
BRPI0818004B8 (pt) 2007-10-16 2021-05-25 Biocon Ltd composição farmacêutica sólida administrável por via oral e o processo da mesma.
WO2009059188A1 (en) 2007-11-02 2009-05-07 Emisphere Technologies, Inc. Method of treating vitamin b12 deficiency
US20090124639A1 (en) 2007-11-06 2009-05-14 Emisphere Technologies Inc. valacyclovir formulations
US20100317057A1 (en) 2007-12-28 2010-12-16 Novo Nordisk A/S Semi-recombinant preparation of glp-1 analogues
RU2504550C2 (ru) 2008-05-16 2014-01-20 Ново Нордиск А/С Длительно действующие агонисты рецепторов y2 и(или) y4
CN102123697B (zh) 2008-08-18 2015-06-10 安特拉贝欧有限公司 用于口服给予蛋白质的方法和组合物
CN106317164A (zh) 2008-09-12 2017-01-11 诺沃—诺迪斯克有限公司 酰化肽或蛋白的方法
US8299023B2 (en) 2008-09-17 2012-10-30 Hoffmann-La Roche Inc. Neuropeptide-2 receptor (Y-2R) agonists
GB0817067D0 (en) 2008-09-18 2008-10-22 7Tm Pharma As Intestinal treatment
PL2386203T3 (pl) 2008-10-15 2014-05-30 Bayer Ip Gmbh Zastosowanie ditiino-tetrakarboksyimidów do zwalczania fitopatogennych grzybów
CA2741921A1 (en) 2008-11-05 2010-05-14 F. Hoffmann-La Roche Ag Neuropeptide-2-receptor (y-2r) agonists and uses thereof
CN101463081B (zh) 2009-01-12 2012-07-04 华东师范大学 一种glp-1衍生物
AU2010212823B2 (en) 2009-02-13 2016-01-28 Boehringer Ingelheim International Gmbh Antidiabetic medications comprising a DPP-4 inhibitor (linagliptin) optionally in combination with other antidiabetics
JP5584236B2 (ja) 2009-02-20 2014-09-03 イプセン ファルマ ソシエテ パール アクシオン サンプリフィエ 神経ペプチドｙ受容体結合化合物を有する細胞毒性コンジュゲート
ITRM20090347A1 (it) 2009-07-03 2011-01-04 Univ Siena Dispositivo di analisi del sistema nervoso centrale attraverso l applicazione di stimoli di diversa natura combinati tra loro e lo studio delle corrispondenti reazioni.
AR077956A1 (es) 2009-09-14 2011-10-05 Bayer Cropscience Ag Combinaciones de compuestos activos
EP2477643A1 (en) 2009-09-18 2012-07-25 Novo Nordisk A/S Long-acting y2 receptor agonists
CA2776302A1 (en) 2009-10-13 2011-04-21 F. Hoffmann-La Roche Ag Neuropeptide-2 receptor (y-2r) agonists
EP2498800A1 (en) 2009-11-13 2012-09-19 Novo Nordisk A/S Long-acting y2 receptor agonists
JP2013514976A (ja) 2009-12-16 2013-05-02 ノッド ファーマシューティカルズ， インコーポレイテッド 経口薬物送達のための組成物および方法
CN104327182B (zh) 2009-12-16 2020-04-17 诺沃—诺迪斯克有限公司 双酰化glp-1衍生物
US20110182985A1 (en) 2010-01-28 2011-07-28 Coughlan David C Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof
WO2011109787A1 (en) 2010-03-05 2011-09-09 Conjuchem, Llc Methods of administering insulinotropic peptides
WO2011116139A2 (en) 2010-03-16 2011-09-22 Chiasma Inc. Improved pharmaceutical compositions and methods of delivery
EP2560675A1 (en) 2010-04-20 2013-02-27 Novo Nordisk A/S Long-acting gastrin derivatives
JP5827218B2 (ja) 2010-04-30 2015-12-02 株式会社三和化学研究所 生理活性物質等の生体内安定性向上のためのペプチド及び生体内安定性が向上した生理活性物質
KR101927068B1 (ko) 2010-05-05 2018-12-10 베링거 인겔하임 인터내셔날 게엠베하 체중 감소 치료에 후속하는 dpp-4 억제제에 의한 순차적 병용 요법
DE202010015867U1 (de) 2010-11-25 2011-05-05 Buchhalter, Thomas Elektromechanische Halterung zur Aufnahme von Navigations- und Kommunikationsgeräte im KFZ
MX345501B (es) 2010-12-16 2017-02-02 Novo Nordisk As Composiciones solidas que comprenden agonista de glp-1 y sal del acido n-(8-(2-hidroxibenzoil)amino)caprilico.
GB201101459D0 (en) 2011-01-27 2011-03-16 Imp Innovations Ltd Novel compounds and thier effects on fedding behaviour
KR101972836B1 (ko) 2011-04-12 2019-04-29 노보 노르디스크 에이/에스 이중 아실화된 ｇｌｐ-1 유도체
CN104271588B (zh) 2011-07-08 2017-10-10 安米林药品有限责任公司 具有增强的作用持续时间和降低的免疫原性的工程改造的多肽
WO2013139695A1 (en) 2012-03-22 2013-09-26 Novo Nordisk A/S Compositions comprising a delivery agent and preparation thereof
HRP20190489T1 (hr) 2012-03-22 2019-05-03 Novo Nordisk A/S Pripravci koji sadrže sredstvo za unošenje i njihova priprava
EP2827885B1 (en) 2012-03-22 2018-08-15 Novo Nordisk A/S Compositions of glp-1 peptides and preparation thereof
WO2013178490A1 (en) 2012-05-29 2013-12-05 Novo Nordisk A/S Pancreatic polypeptide compounds and use
US9993430B2 (en) 2012-06-20 2018-06-12 Novo Nordisk A/S Tablet formulation comprising semaglutide and a delivery agent
HRP20251088T1 (hr) 2012-07-01 2025-11-07 Novo Nordisk A/S Upotreba dugodjelujućih peptida glp‑1
SMT201800492T1 (it) 2013-05-02 2018-11-09 Novo Nordisk As Dosaggio orale di composti di glp-1
UY35548A (es) 2013-05-02 2014-11-28 Glaxosmithkline Ip No 2 Ltd Péptidos terapéuticos para el tratamiento de trastornos metabólicos.
AU2014350197B2 (en) 2013-11-15 2018-10-04 Novo Nordisk A/S Selective PYY compounds and uses thereof
EP3068795B1 (en) 2013-11-15 2019-03-06 Novo Nordisk A/S Hpyy(1-36) having a beta-homoarginine substitution at position 35
JP6925969B2 (ja) 2015-02-09 2021-08-25 エンテラ バイオ エルティーディー． 医薬組成物
AU2016275735B2 (en) 2015-06-12 2020-02-06 Novo Nordisk A/S Selective PYY compounds and uses thereof
CA2997343A1 (en) 2015-10-07 2017-04-13 Cyprumed Gmbh Pharmaceutical formulations for the oral delivery of peptide drugs
EP4299118A3 (en) 2018-02-02 2024-04-10 Novo Nordisk A/S Solid compositions comprising a glp-1 agonist, a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant

Also Published As

Publication number Publication date
PL3326620T3 (pl) 2020-08-24
LT2651398T (lt) 2018-03-26
KR101925620B1 (ko) 2018-12-05
WO2012080471A1 (en) 2012-06-21
US10086047B2 (en) 2018-10-02
US20230302092A1 (en) 2023-09-28
US20210177944A1 (en) 2021-06-17
JP2016117759A (ja) 2016-06-30
PT2651398T (pt) 2018-03-09
JP2014503526A (ja) 2014-02-13
HUE036066T2 (hu) 2018-06-28
EP3326620A1 (en) 2018-05-30
AU2011343190A1 (en) 2013-06-06
US10960052B2 (en) 2021-03-30
EP2651398B1 (en) 2017-12-13
RS56998B1 (sr) 2018-05-31
US11382957B2 (en) 2022-07-12
US20220313786A1 (en) 2022-10-06
MX345501B (es) 2017-02-02
RU2600440C3 (ru) 2021-12-10
MX377589B (es) 2025-03-10
AU2011343190B2 (en) 2016-12-08
EP2651398A1 (en) 2013-10-23
ES2661676T3 (es) 2018-04-03
RU2013131913A (ru) 2015-01-27
CA2821886A1 (en) 2012-06-21
US20180360918A1 (en) 2018-12-20
US20240277817A1 (en) 2024-08-22
JP5902194B2 (ja) 2016-04-13
CN103260608A (zh) 2013-08-21
PL2651398T3 (pl) 2018-05-30
SI2651398T1 (en) 2018-04-30
BR112013014942A2 (pt) 2017-05-30
RU2600440C2 (ru) 2016-10-20
EP3730127A1 (en) 2020-10-28
SMT201800117T1 (it) 2018-05-02
DK3326620T3 (da) 2020-05-25
KR20140030116A (ko) 2014-03-11
DK2651398T3 (en) 2018-03-12
BR112013014942B1 (pt) 2020-01-28
EP3326620B1 (en) 2020-03-04
SI3326620T1 (sl) 2020-07-31
CN105963685A (zh) 2016-09-28
MX2013006171A (es) 2013-07-15
RS60321B1 (sr) 2020-07-31
US20160151462A1 (en) 2016-06-02
US9278123B2 (en) 2016-03-08
US20130345134A1 (en) 2013-12-26
CN105963685B (zh) 2021-01-15

Similar Documents

Publication Publication Date Title
HRP20180425T1 (hr) Čvrste kompozicije koje sadrže agonist glp-1 i sol n-(8-(2-hidroksibenzoil)amino)kaprilne kiseline
MY174002A (en) Combination theraphy for the treatment of diabetes
RU2015147876A (ru) Пероральная дозированная форма соединений глюкагоноподобного пептида-1
HRP20171175T1 (hr) Novi triciklički spojevi
HRP20251088T1 (hr) Upotreba dugodjelujućih peptida glp‑1
JP2014503526A5 (enExample)
BR112015005972A2 (pt) derivados do tipo amida de ácido benzoimidazol-carboxílico como moduladores do receptor apj
HRP20220902T3 (hr) Pripravci i njihova upotreba u liječenju multiple skleroze
HRP20151000T1 (hr) Antivirusni spojevi
RU2641198C3 (ru) Композиции glp-1 пептидов и их получение
HRP20181028T2 (hr) Dugodjelujuće formulacije inzulina
JO2973B1 (en) Fumarate salt for (alpha-beta-R) -6-bromo-alpha-[2- (methylamino) ethyl-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinoline ethanol
WO2013101897A3 (en) Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid
BR112013032122A2 (pt) liberação modificada de 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluorometil)fenil] benzamida solubilizada usando ácidos orgânicos
HRP20250102T1 (hr) Pth spojevi s kontroliranim oslobađanjem
PE20081578A1 (es) Formulacion en polvo de valganciclovir
MY160728A (en) Morpholinothiazoles as alpha 7 positive allosteric modulators
UA109421C2 (uk) Фармацевтична композиція, яка містить ліганди сигма-рецептора
HRP20171648T1 (hr) Supstituirani piperidil-etil-pirimidin kao inhibitor grelin-o-acil-transferaze
HRP20151230T1 (hr) Liksisenatid kao dodatak metforminu kod lijeäśenja dijabetesa tipa 2
JP2014532722A5 (enExample)
MX383551B (es) Derivados de glutarimida, uso de los mismos, composicion farmaceutica basada en los mismos y metodos para producir derivados de glutarimida
JP2011026348A5 (enExample)
FI3229828T3 (fi) Glargiini-insuliinin/liksisenatidin vakiosuhteinen formulaatio
HRP20200332T1 (hr) Modifikator eksenatida i njegova primjena